MedTrace Logo

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

NCT05022784 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1798

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program.

This study has two objectives:

* Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients.
* Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.

Conditions

Interventions

DRUG

Nintedanib

Nintedanib

Sponsors & Collaborators

Eligibility

Min Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2021-12-30
Completion
2021-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05022784 on ClinicalTrials.gov